83results about How to "Reduced dysfunction" patented technology

Devices, systems and methods for treating medical conditions using cell therapy via body lumens. Localized delivery is achieved with the use of a stent-like expandable body seeded with cells. The expandable body is expanded to contact at least a portion of the inner walls of the body lumen and the cells, cellular products and/or other therapeutic agents are delivered to the surrounding tissue. The therapeutic benefit provided is dependent on the type of cells used and the features of the expandable body.

An apparatus for assessing cardiovascular status of a mammal comprises a system for locally applying a pressure to an artery capable of restricting blood flow through said artery, a wideband external pulse transducer having an output and situated to measure suprasystolic signals proximate to said artery, and a computing device receiving said output for calculating vascular compliance values. The method described is particularly useful for determining cardiac output, assessing whether a pregnant female has preeclampsia or a patient has cardiac insufficiency, or assessing cardiac arrhythmias.

An apparatus for assessing cardiovascular status of a mammal comprises a system for locally applying a pressure to an artery capable of restricting blood flow through said artery, a wideband external pulse transducer having an output and situated to measure suprasystolic signals proximate to said artery, and a computing device receiving said output for calculating vascular compliance values. The method described is particularly useful for determining cardiac output, assessing whether a pregnant female has preeclampsia or a patient has cardiac insufficiency, or assessing cardiac arrhythmia.

Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin are disclosed. In particular, the invention relates to formulations comprising apelin encapsulated in liposome nanocarriers conjugated with polyethylene glycol (PEG) and their use in treatment of cardiovascular and pulmonary diseases and disorders. Encapsulation of apelin in PEG-conjugated liposomes significantly enhances efficacy, improves cellular uptake of apelin, and allows for sustained and extended release of apelin under physiological conditions.

Light energy, preferably at a wavelength of 884 nanometers, is applied to the genitalia area of male and female humans and animals to treat erectile sexual dysfunction. The light causes the release of nitric oxide into the erectile genitalia tissue, and the nitric oxide causes the smooth erectile tissue to relax and engorge, thereby facilitating erection. Separately structured applicators for males and females optimize the degree of light energy penetration and the amount of nitric oxide released according to the separate physiology of males and females. The light energy may be used to augment a pharmacologically-induced release of nitric oxide.

System for optimization of production with added value and for integration of the best business practices, which is characterized in that it includes two base modules of services application software, said first base being a central module A connected, for data extraction, with the organization information system or database for the anticipation of costs and for the control of the piloting, common to all the models, said second base being a peripheral module B of learning acceleration and to structuring of technical information actionable by the user, said second module B being an interface connected to the first module A by the connection C.

The present invention relates to pharmaceutical preparations and methods for treating individuals infected with the human immunodeficiency virus (HIV). The pharmaceutical preparations comprise an immunomodulating agent and a anti-retroviral compound. The pharmaceutical preparations are used to treat HIV infected patients, particularly for gastrointestinal complications arising from viral infection. In addition, the pharmaceutical preparations of the present invention have the effect of raising the levels of CD4⁺ single positive and CD4⁺ and CD8⁺ double positive T cells, thus promoting restoration and normalization of the immune system following HIV infection.

The invention provides an eyelid massager which comprises a binding part used for being bound with the head of a user, a fixing part arranged at the front end of the binding part, a driving part installed on the fixing part in a rotation mode, a massaging part arranged by corresponding to the eyes, connected with the driving part and used for massaging the eyes under the drive of the driving part and a switch used for starting or stopping the driving part. The massaging part comprises upper eyelid massaging balls corresponding to the upper eyelids of the eyes and lower eyelid massaging balls corresponding to the lower eyelids of the eyes. The driving part is used for driving the upper eyelid massaging balls to extrude and massage the upper eyelids from top to bottom repeatedly and at the same time, driving the lower eyelid massaging balls to extrude and massage the lower eyelids from bottom to top repeatedly. The upper eyelids and the lower eyelids of the user are massaged specifically. The manner of increasing the pressure is used for discharging thick and dense secreta in the meibomian glands so as to eliminate jamming of the meibomian glands and achieve the aim of promoting smooth secretion of the meibomian glands.

The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided.

Methods and pharmaceutical compositions for treatment of amyloid deposition diseases using chimeric (e.g., mouse-human) antibody are disclosed, including a method for treating amyloid deposition diseases with cardiac involvement by administering pharmaceutical compositions comprising a chimeric anti-amyloid fibril antibody. The methods herein can improve myocardial function in patients diagnosed with light chain amyloid light chain amyloidosis (ALA) having a cardiac involvement in as little as three weeks after treatment.

This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.

A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.

The invention discloses a composition based on stem cells and application thereof in preparing preparation for the coronary heart disease. The composition based on the stem cells includes the stem cells prepared through an optimizing method and cell preserving liquid serving as a solvent. Firstly, proper stem cells are selected; secondly, the selected stem cells are further processed through the optimizing method; lastly, the stem cells are collected and resuspended in the cell preserving liquid. A various cell implanting method is adopted in the application of the composition based on the stem cells in preparing the preparation for the coronary heart disease, the time nodes before an operation, during the operation and after the operation are combined, and it is ensured that the transplanted stem cells can give the full play. The optimizing method is used for preparing the stem cells and the stem cell composition in the cell preserving liquid, the ventricle function can be extremely obviously enhanced after cell transplantation, and the left ventricle reconstitution is restrained. The optimal cell composition is provided for treating the coronary heart disease, the source is wide, preparation is simple, toxic and side effects are avoided, and the transplanting effect is good.

Disclosed is the use of a gold cluster or a gold cluster-containing substance in the preparation of a drug for preventing and/or treating glaucoma.

The invention pertains to a composition comprising (i) uridine in nucleobase, nucleoside and/or nucleotide form; (ii) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); and (iii) a tocopherol and/or an equivalent thereof, wherein said composition has: a) a weight of 200-3000 mg per unit dose; b) an energy content of less than 50 kcal per unit dose; and/or c) a volume between 0.1 and 10 ml per unit dose. The invention also pertains to the use of such composition in reducing abeta plaque burden and neurodegeneration, in the treatment of diseases related with imparted nerve functioning, in particular dementia, Alzheimer's disease and memory disorders.

Provided herein are methods for using a thrombin peptide derivative to treat a medulloblastoma. In one embodiment, the method includes administering to a subject having a medulloblastoma an effective amount of a thrombin peptide derivative, and exposing cells of the medulloblastoma of the subject to a cancer treatment after administering the thrombin peptide derivative to the subject. An example of a cancer treatment is radiation therapy. In one embodiment, viability of cells of the medulloblastoma is decreased compared to viability of cells of the medulloblastoma before the administering and the exposing. The cells of the medulloblastoma having decreased viability can be cancer stem cells. In one embodiment, shrinkage of the medulloblastoma in the subject is increased compared to shrinkage of the medulloblastoma before the administering and the exposing.

The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.